-
1 week ago | 
rheumnow.com | Jack Cush
Dr. Jack Cush reviews the news, journal reports and lupus highlights from the past week on RheumNow.com. Triple positivity, the gut and CRPS, and hope for better outcomes with Vitamin D therapy. • Congrats to Dr. Virginia Pascual who was elected to American Academy of Arts and Sciences.
-
1 week ago | 
rheumnow.com | Jack Cush
Vitamin D plays an important role in immune function and in the VITAL study was shown to reduce the risk of autoimmune disease. Also a deficiency of vitamin D, can be a risk factor for multiple sclerosis (MS). This study assessed whether high-dose cholecalciferol monotherapy in may influence signs of developing MS. The D-Lay MS trial was a parallel, double-blind, randomized placebo-controlled clinical trial in France.
-
1 week ago | 
rheumnow.com | Jack Cush
An open-label, single-centre, randomized controlled trial tested whether immunosuppressant (IS) withdrawal is noninferior to glucocorticoid (GC) withdrawal in systemic lupus erythematosus (SLE) patients and found that IS withdrawal is noninferior to GC withdrawal in SLE patients in long-term clinical remission. A total of 121 adult SLE patients were enrolled if they were in clinical remission for ≥1 year, on stable GC (prednisolone ≤7.5 mg/day) and on maintenance non-biological IS for ≥3 years.
-
2 weeks ago | 
rheumnow.com | Jack Cush
Dr. Jack Cush reviews the news, articles and drug approvals from the past week on RheumNow.com. This podcast marks the beginning of our Lupus Campaign called "Lupus Unlocked: Keys to Mastery". THis months campaign on Lupus is sponsored by Aurinia. • FDA Approves Rinvoq for Giant Cell Arteritis Based on the results of the SELECT-GCA study, the US FDA has approved upadacitinib (Rinvoq or UPA) for the treatment of adults with giant cell arteritis (GCA), also known as temporal arteritis.
-
2 weeks ago | 
rheumnow.com | Jack Cush
An emulation trial of sodium–glucose cotransporter 2 inhibitors (SGLT2i) in systemic lupus erythematosus (SLE) patients yielded a significantly reduced risk of several cardiorenal complications among patients with SLE and type 2 diabetes (T2D). Using insurance-based cohort data and a clinical trial emulation, SLE patient outcomes were compared in those with T2D who received either SGLT2i or dipeptidyl peptidase-4 inhibitors.
-
2 weeks ago | 
rheumnow.com | Jack Cush
FIRST is a Japanese longitudinal, real world, registry of rheumatoid arthritis (RA) management and over the las 20 years has shown significantly improved outcomes, yet significant challenges and unmet needs remain. FIRST registry is a multicenter cohort of patients with RA treated with biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs). Between 2003 and 2023, patients were followed for 60 months and assessed for drug efficacy, retention, and reasons for discontinuation.
-
2 weeks ago | 
rheumnow.com | Jack Cush
Based on the results of the SELECT-GCA study, the US FDA has approved upadacitinib (Rinvoq or UPA) for the treatment of adults with giant cell arteritis (GCA), also known as temporal arteritis. This is the 9th FDA approved indication for upadacitinib U.S. for use in rheumatology, gastroenterology, and dermatology. GCA affects elderly adults with a large vessel vasculitis; and isthe most common vasculitis affecting adults in Western countries.
-
2 weeks ago | 
rheumnow.com | Jack Cush
A EULAR/PReS combined task force has developed recommendations for the management of Familial Mediterranean fever (FMF), the most common monogenic autoinflammatory disease worldwide. These evidence-based recommendations update the 2016 recommendations developed for rheumatologists and other HCPs who care for FMF patients. A multidisciplinary panel reviewed new literature and evidence and voted recommendations via a Delphi survey. They propposed 4 overarching principles and 12 recommendations.
-
2 weeks ago | 
rheumnow.com | Jack Cush
Key TakeawaysLimited evidence has suggested that metformin could reduce some of the pathology underlying osteoarthritis (OA). Researchers conducted a small randomized trial to assess metformin's effectiveness in knee OA, with pain intensity after 6 months as the primary outcome. Metformin produced significantly more pain relief than was seen in a placebo group, although the difference was of marginal clinical importance.
-
3 weeks ago | 
rheumnow.com | Jack Cush
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Should we believe the reviews and metanalyses? • Retrospective EGPA study of mepolizumab Rx 45 pts Rx initially w/ 300 mg/4 weeks, 27% switched to 100 mg/4 wks after 26 mos & 50% maintained complete remission without GC. Other half had sinonasal Sxs Rx w/ increased MEP dose orlocal therapy. https://buff.ly/pRU4Uhv• IL-17 inhibitors increase risk of IBD.
